All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Izalontamab Brengitecan Data Reinforce the Value of ADCs in Advanced Urothelial Carcinoma

October 15th 2025

Izalontamab brengitecan showed signals of activity in patients with pretreated locally advanced or metastatic urothelial carcinoma.

Expanding Radioligand Options Redefine mCRPC Management and Individualize Patient Care

October 15th 2025

Alicia Morgans, MD, MPH, discusses the role of radioligand therapies for mCRPC and the importance of shared decision-making in prostate cancer management.

Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer

October 15th 2025

Chemoradiotherapy improved survival vs radiotherapy alone in the adjuvant setting in high-risk endometrial cancer, particularly in p53-abnormal disease.

Genetic “Trojan Horse” Selectively Kills Cancer Cells Linked to Kaposi’s Sarcoma

October 15th 2025

Targeted gene therapy kills herpesvirus-linked cancer cells, sparing healthy tissue

FDA Approval of TAR-200 Represents Potential Bladder-Sparing Option in BCG-Unresponsive NMIBC

October 15th 2025

Joseph Jacob, MD, MCR, discusses the significance of the FDA approval of TAR-200 for BCG-unresponsive non–muscle-invasive bladder cancer.

FDA Grants Fast Track Status to NG-350A for pMMR Locally Advanced Rectal Cancer

October 15th 2025

NG-350A has been awarded fast track designation from the FDA for rectal cancer and is under further evaluation in the FORTRESS trial.

Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer

October 15th 2025

Maintenance rucaparib showed efficacy in recurrent/metastatic endometrial cancer after the completion of first- or second-line chemotherapy.

EU Approval Sought for Relacorilant in Platinum-Resistant Ovarian Cancer

October 14th 2025

The approval of relacorilant for use in patients with platinum-resistant ovarian cancer is sought from the European Medicines Agency.

PEACE-3 Data Add to Expanding Evidence Clarifying Radium-223 Use in mCRPC

October 14th 2025

Alicia Morgans, MD, MPH, discusses data from the PEACE-3 trial that support the use of radium-223 plus enzalutamide in patients with mCRPC.

‘Google Maps’ Approach to Revolutionize Lung Cancer Treatment

October 14th 2025

Researchers developed a way to predict how lung cancer cells will respond to different therapies, allowing for more effective individualized treatment.

64Cu-SAR-bisPSMA Bests SOC 68Ga-PSMA-11 PET/CT in Detecting PSMA-Positive Prostate Cancer Lesions

October 14th 2025

64Cu-SAR-bisPSMA displayed a higher detection rate of PSMA-positive prostate cancer lesions vs 68Ga-PSMA-11 PET/CT in patients with low PSA levels.

Tucatinib Plus Trastuzumab and Pertuzumab Maintenance Improves PFS in HER2+ Metastatic Breast Cancer

October 14th 2025

Combining tucatinib with trastuzumab and pertuzumab improved PFS as first-line maintenance in patients with HER2-positive metastatic breast cancer.

Niraparib Plus AAP Could Represent New Standard Option for mCSPC With HRR Gene Alterations

October 14th 2025

The AMPLITUDE trial met its primary end point of rPFS with niraparib regimen vs placebo in metastatic castration-sensitive prostate cancer.

Teclistamab-Based Induction Regimens Deepen Responses in Newly Diagnosed Multiple Myeloma

October 14th 2025

Marc S. Raab, MD, discusses updated MRD negativity and safety data with teclistamab plus SOC induction regimens in newly diagnosed multiple myeloma.

Baseline Cardiovascular Assessment, Monitoring Are Crucial With BTK Inhibitors in CLL and Other Hematologic Malignancies

October 14th 2025

A meta analysis found BTK inhibitors carry risks of hypertension, atrial fibrillation, and hemorrhage, underscoring the need for cardiovascular monitoring.

Tarlatamab Demonstrates Early Safety and Activity in DLL3+ Neuroendocrine Prostate Cancer

October 13th 2025

DeLLpro-300 data provide preliminary evidence for the safety and activity of tarlatamab in DLL3-positive neuroendocrine prostate cancer.

Olaparib Withstands the Test of Time With Long-Term Data Supporting Its Role in Ovarian Cancer Treatment

October 13th 2025

Kevin Elias, MD, discusses the role of olaparib in the management of ovarian cancer.

Countdown to ESMO 2025: Catch Up on OncLive’s Extensive Tumor-Specific Previews

October 13th 2025

Preview the top lung, breast, GI, GU, gynecologic, and hematologic oncology abstracts and topics ahead of the 2025 ESMO Congress.

CELMoDs Could Augment T-Cell Redirection Therapies for Prolonged Remission in R/R Myeloma

October 13th 2025

Joshua Richter, MD, discusses the use of next-generation CELMoDs to boost T-cell responses with bispecific antibodies or CAR T-cell therapy in myeloma.

Roswell Park Joins Other Leading Cancer Centers in Reinforcing Importance of HPV Vaccination to Prevent Cancer

October 13th 2025

Roswell Park Comprehensive Cancer Center endorsed a statement urging health care systems and professionals to choose HPV vaccination for cancer prevention.